Search

This document is a correction notice for an article on cell therapy for anal sphincter incontinence. The authors have made corrections to the citations and reference numbers, as well as updated the references in Table 1. Table 3 provides information on the characteristics of primary cells proposed for cell therapy of anal sphincter incontinence. The document also discusses the use of cell therapy for anal sphincter injury, including various studies and clinical trials. It highlights the practical considerations and challenges associated with cell therapy, as well as the need for further research in this area. Additionally, the document is part of a collection of articles exploring regenerative therapies for anal sphincter injury and fecal incontinence, providing valuable insights for researchers and healthcare professionals. [Extracted from the article]

Anal sphincter incontinence is a chronic disease, which dramatically impairs quality of life and induces high costs for the society. Surgery, considered as the best curative option, shows a disappointing success rate. Stem/progenitor cell therapy is pledging, for anal sphincter incontinence, a substitute to surgery with higher efficacy. However, the published literature is disparate. Our aim was to perform a review on the development of cell therapy for anal sphincter incontinence with critical analyses of its pitfalls. Animal models for anal sphincter incontinence were varied and tried to reproduce distinct clinical situations (acute injury or healed injury with or without surgical reconstruction) but were limited by anatomical considerations. Cell preparations used for treatment, originated, in order of frequency, from skeletal muscle, bone marrow or fat tissue. The characterization of these preparations was often incomplete and stemness not always addressed. Despite a lack of understanding of sphincter healing processes and the exact mechanism of action of cell preparations, this treatment was evaluated in 83 incontinent patients, reporting encouraging results. However, further development is necessary to establish the correct indications, to determine the most-suited cell type, to standardize the cell preparation method and to validate the route and number of cell delivery. [ABSTRACT FROM AUTHOR]